Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Amortization of Deferred Charges (2020 - 2025)

Maravai Lifesciences Holdings has reported Amortization of Deferred Charges over the past 6 years, most recently at $403000.0 for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $403000.0 for Q4 2025, down 38.75% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (down 42.89% YoY), and the annual figure for FY2025 was $1.7 million, down 42.89%.
  • Amortization of Deferred Charges for Q4 2025 was $403000.0 at Maravai Lifesciences Holdings, up from $399000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for MRVI hit a ceiling of $900000.0 in Q3 2021 and a floor of $391000.0 in Q2 2025.
  • Median Amortization of Deferred Charges over the past 5 years was $711000.0 (2022), compared with a mean of $658000.0.
  • Biggest five-year swings in Amortization of Deferred Charges: tumbled 96.56% in 2021 and later increased 13.61% in 2023.
  • Maravai Lifesciences Holdings' Amortization of Deferred Charges stood at $681000.0 in 2021, then fell by 3.96% to $654000.0 in 2022, then grew by 13.61% to $743000.0 in 2023, then dropped by 11.44% to $658000.0 in 2024, then crashed by 38.75% to $403000.0 in 2025.
  • The last three reported values for Amortization of Deferred Charges were $403000.0 (Q4 2025), $399000.0 (Q3 2025), and $391000.0 (Q2 2025) per Business Quant data.